Table 2.
Mean street prices from crowdsourced data, adjusted for potency relative to morphine, United States, 2012.
| Drug | Crowdsourced Data from StreetRx | Predicted Relative Potency | Clinical Equianalgesic Potencyb | |
| n | Mean, US$ (95% CI) | (95% CI)a | Milligrams | |
| Hydromorphone | 75 | 3.29 (2.74-3.96) | 6.3 (5.8-6.8) | 4 |
| Oxymorphone | 38 | 1.57 (1.27-1.95) | 3.0 (2.9-3.2) | 3 |
| Methadone | 21 | 0.96 (0.71-1.29) | 1.8 (1.8-1.9) | 1.5 |
| Oxycodone | 454 | 0.97 (0.90-1.04) | 1.9 (1.5-2.2) | 2 |
| Hydrocodone | 228 | 0.81 (0.74-0.89) | 1.5 (1.3-1.8) | 1 |
| Morphine | 83 | 0.52 (0.40-0.68) | 1.0 | 1 |
| Tramadol | 21 | 0.05 (0.03-0.07) | 0.1 (0.07-0.13) | 0.3 |
aPredicted relative potency refers to the potency or desirability as predicted by the street price relative to morphine. It was calculated by standardizing the price per milligram for each opioid against that of morphine. These numbers do not distinguish oral from other routes of administration, nor take into account time-release mechanisms. They should not be used for clinical conversion.
bSource: United States Veterans Administration/Department of Defense Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain, 2012.